Clinical trial · Interventional
Radiation Therapy in Treating Patients With Aggressive Fibromatoses
Phase II Pilot Study Of Moderate Dose Radiotherapy For Inoperable Aggressive Fibromatoses
NCT00030680CI-TRIAL-00011934completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients who have aggressive fibromatoses.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Desmoid Tumor | Desmoid Fibromatosis | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Local control as assessed by MRI at 3 years
Secondary outcomes (2)
- measure
- Toxicity as assessed by CTC 2.0
- measure
- Response as assessed by MRI
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed aggressive fibromatoses arising in any site
* Primary, recurrent, or progressive disease that is inoperable or requires a major operation resulting in a large functional or cosmetic deficit or mutilation
* Progressive disease defined as at least 20% increase in tumor size on 2 MRI scans within 1 year after any prior therapy except radiotherapy OR
* Incompletely resected tumor with gross residual disease not suitable for further surgery
* Resected within the past 3 months
* Lesions must be suitable for radiotherapy
* No bulky intra-abdominal disease in close relation to small bowel
* Measurable disease
PATIENT CHARACTERISTICS:
Age:
* 16 and over
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Not specified
Other:
* No conditions that would preclude study follow-up
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* Prior chemotherapy allowed
* No concurrent chemotherapy
Endocrine therapy:
* Prior endocrine therapy allowed
* No concurrent endocrine therapy
Radiotherapy:
* See Disease Characteristics
* No prior radiotherapy to indicator lesion
Surgery:
* See Disease Characteristics
* Prior surgery allowed
Other:
* No prior isolated limb perfusion with tumor necrosis factor
* No concurrent isolated limb perfusion with tumor necrosis factorReferences
Publications (0)
Data not yet available
No reference posted for this study.